Thiogenesis Announces Extension to Investor Relations Agreement #InvestmentBanking #Agreement #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds to treat unmet pediatric diseases, announces the extension of its investor relations agreement with Triomphe Holdings Ltd., doing business as Capital Analytica (Consultant) for a further 3-month...
http://dlvr.it/TNSXvD
http://dlvr.it/TNSXvD
Comments
Post a Comment